News
-
Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System
Hemanext Inc. announced today it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the…
Read More » -
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
Read More » -
Blood Donors’ COVID-19 Antibodies: Do They Have A Positive Significance for Blood Recipients?
According to recent data released by the American Red Cross, in the first week of March 2021 more than 20% of blood donations from unvaccinated people in the US had…
Read More » -
-
COMING UP: New TIF Webinar On ”COVID-19 Vaccinations & Patients With Haemoglobin Disorders”
TIF is delighted to inform you that a Special Webinar on ‘’COVID-19 Vaccinations & Patients with Haemoglobin Disorders’’ will take place on Wednesday, 31 March 2021, at 14:30-16:00 EEST/12:30-14:00 GMT.…
Read More » -
A Head-to-Head Comparison of BMT, Gene Therapy & Gene Editing Through A Brand New TIF Infographic
The expansion of management options and therapies for patients with thalassaemia is nowadays a reality, thanks to the application of new, revolutionary scientific procedures. However, patients’ understanding on the distinct…
Read More » -
TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10%…
Read More » -
Out Now: The Latest Issue of TIF’s COVID-19 Vaccinations Update
Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing a…
Read More » -
TIF SURVEY | Sickle Cell Disease Patients’ Views on Oxbryta
OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved treatment that directly inhibits sickle hemoglobin polymerization, the root cause…
Read More » -
TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty
Two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations, including the Thalassaemia International Federation (TIF), and hundreds of thousands of patients, researchers…
Read More »